A bipartisan bill aimed at helping terminally ill patients gain access to experimental medicines would leave intact the controversial role of the Food and Drug Administration, a notion that will likely upset backers of the so-called right-to-try movement.

The draft legislation, which is being developed with help from the FDA, also includes a provision that seeks to reassure anxious drug makers about making their treatments available, but to what extent this move makes the effort easier to forge a compromise is uncertain.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Ah, an interesting point of view – “we don’t believe the government should have a role in that decision-making process once a drug is determined to be safe enough to give to people in human trials,” said Starlee Coleman, a spokeswoman for the Goldwater Institute” – but there is a true difference between safe enough for trials and ‘safe and effective.’
    Trials do surprise, don’t they? I will demure from providing examples.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy